Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
about
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.Long QT Syndrome: An Emerging Role for Inflammation and ImmunityVentricular repolarization measures for arrhythmic risk stratificationClinical effectiveness of dolutegravir in the treatment of HIV/AIDSCo-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric PatientsA 26-year-old woman with recurrent loss of consciousness.Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.Rare genetic variants previously associated with congenital forms of long QT syndrome have little or no effect on the QT interval.Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide.Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility--consensus guideline by International Society for Holter and Noninvasive Electrocardiology.Causes and management of drug-induced long QT syndrome.Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-c2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of ADofetilide induced torsade de pointes: mechanism, risk factors and management strategies.The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial.Cardiac risks associated with antibiotics: azithromycin and levofloxacinPostoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesiaEffectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot StudyEffect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.Multi-factorial causes of torsade de pointes in a hospitalised surgical patient.QT ProlongationPrevalence and prognostic significance of long QT interval among patients with chest pain: selecting an optimum QT rate correction formula.Mechanisms of drug-induced proarrhythmia in clinical practice.Perioperative torsade de pointes: a systematic review of published case reportsDevelopment and validation of a risk score to predict QT interval prolongation in hospitalized patients.Gene-environment interaction between SCN5A-1103Y and hypokalemia influences QT interval prolongation in African Americans: the Jackson Heart Study.Methadone, QTc prolongation and torsades de pointes: Current concepts, management and a hidden twist in the tale?Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation.Droperidol for the treatment of acute migraine headaches.Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial.Drug-associated arrhythmia in the military patient.The clinical significance of QT prolongation associated with tamoxifen: A review of the literature.Should We be Worried About QTc Prolongation Using Citalopram? A Review.Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database.Development of a risk score for QTc-prolongation: the RISQ-PATH study.Risk factors for QTc-prolongation: systematic review of the evidence.Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.A Case of Hypoglycemiainduced QT Prolongation Leading to Torsade de Pointes and a Review of Pathophysiological Mechanisms.
P2860
Q24605881-0AAA77EE-B357-47B1-BA14-AF428C25C159Q26769710-0F18170F-B462-4C3E-8348-69E488C75D01Q26769982-587FDD3E-AF60-4925-A85D-7AE3368B482CQ26778450-1631C53D-EF9D-4671-849D-6283F05379CCQ28552117-49AC72E9-7541-47C5-A026-1E9BED927EB3Q30460335-ED12390C-4DD1-4EAA-98E2-FD7AC54B9A46Q30823425-3A8B2A1F-2A6B-409C-986F-B76136CB1D19Q33165997-3AACD98D-9C52-400F-BE87-BC0D35277677Q33447922-79C02AEE-BBCA-49C8-9BA9-7247B3DDE424Q33952439-AB2DC561-212A-4FC5-BE09-FDE205E2AE96Q33979442-7CA885A5-C32D-43F0-ADF2-9F373B9F70A6Q34165538-99756AB6-8E30-46D5-960A-1893EDC6832CQ34431980-5E724858-7BCE-43C1-83FA-553E8A072B3BQ35028720-29ED5A60-B1EC-4E88-886F-8BE5977BC4ECQ35177083-6ED32AFE-E9BF-4B3C-BE87-155032882F59Q35502601-C4D25884-41F7-4187-A036-36F944424AF4Q36120691-25F5973F-A122-444E-9DF1-3CD4879A35F9Q36418252-AF224240-6BD9-41F7-8D88-789CDE3129D3Q36514742-104BC372-2B61-45B0-87D8-A744F4BDE3D9Q36527332-3F460EC5-1214-4F7F-977D-170AC4215978Q36667015-7903E56C-F812-4755-BC36-300B1A88C0BCQ36741055-AC849495-B5BC-4DCE-A8D7-30EBDA0C3F94Q36882435-EF994880-382B-4349-A174-D9036A15C473Q36980086-37D80136-7FBF-4AAC-8E6B-3732B2DE5B15Q37001536-2FF97A59-921A-4A75-897C-E222B38053B6Q37112546-0A395482-F7E8-4B69-BF27-59C0BD367A4DQ37211037-C3721A28-1CC9-474F-BAFD-379893B217BEQ37448379-1960EF2A-0D85-4A16-B093-5839668B7F9EQ37636417-CB988568-A9D3-481B-880D-4B172EE9128BQ38155163-5279FE75-1F71-4180-AFEA-CE5B22E593A9Q38270424-C3B64D68-0394-47A8-A8A6-108A9E827DC0Q38381113-758B5633-AFEC-495A-9990-D760CB087774Q38566602-EACF37D0-7F33-4AEF-98B9-13FF2D3CFAE5Q38669660-6C8340AF-852F-4F1C-8A7C-56432F9CC746Q38695559-6054F11A-C33A-4569-BB40-872D9BF7E112Q38881765-B668E0FE-EA3D-4207-BEAC-02469CD95F1BQ38915495-6357F2F2-1B59-48CE-B18A-D7A8E55C5240Q39052301-2C18925B-02DA-4A69-B647-DF48B57B8A89Q39147393-D9002899-FE0A-47B5-BF85-71BB38CF0741Q39399853-CEE9A573-68BA-45B8-9632-C1177AAE9791
P2860
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prevention of torsade de point ...... lege of Cardiology Foundation.
@ast
Prevention of torsade de point ...... lege of Cardiology Foundation.
@en
Prevention of torsade de point ...... lege of Cardiology Foundation.
@nl
type
label
Prevention of torsade de point ...... lege of Cardiology Foundation.
@ast
Prevention of torsade de point ...... lege of Cardiology Foundation.
@en
Prevention of torsade de point ...... lege of Cardiology Foundation.
@nl
prefLabel
Prevention of torsade de point ...... lege of Cardiology Foundation.
@ast
Prevention of torsade de point ...... lege of Cardiology Foundation.
@en
Prevention of torsade de point ...... lege of Cardiology Foundation.
@nl
P2093
P2860
P50
P1476
Prevention of torsade de point ...... lege of Cardiology Foundation.
@en
P2093
American Heart Association Acu ...... Council on Clinical Cardiology
Barbara J Drew
Dan M Roden
George J Philippides
Marjorie Funk
Michael J Ackerman
Paul Kligfield
Venu Menon
W Brian Gibler
P2860
P304
P356
10.1016/J.JACC.2010.01.001
P407
P577
2010-03-01T00:00:00Z